1700. Efficacy and Safety in Subjects with Renal Impairment in Contezolid and Contezolid Acefosamil Phase 2 and Phase 3 Skin Infection Clinical Trials

BACKGROUND: Contezolid (CZD; MRX-I) is a novel oral (PO) oxazolidinone with potent activity against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enteroccocus (VRE). Contezolid acefosamil (CZA; MRX-4) is an intravenous (IV) double prod...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Edward, Yang, Huahui, Yuan, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752584/
http://dx.doi.org/10.1093/ofid/ofac492.1330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752584/
http://dx.doi.org/10.1093/ofid/ofac492.1330

Ejemplares similares